Search Results

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Closing Remarks. Lunch and farewell Date & Time Saturday, November 4th / 12:30 PM Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

<< Back to podcast list Strategic Partner(s) Dr. Robert F. Bruns About Dr. Robert F. Bruns Fred Bruns discovered the first positive allosteric modulator (PAM) of a GPCR in the late 1980s while working at Warner-Lambert/Parke-Davis. The work was published in 1990. After 7 years at WL/PD and 26 years at Eli Lilly & Co., he retired at the end of 2014 and since then has been writing papers on his final major project at Lilly, a dopamine D1 PAM series that has advanced through Phase 2 clinical trials. Fred obtained an A.B. in Psychology from Washington University in St. Louis, followed by a Ph.D. in Neurosciences at the University of California, San Diego. His doctoral dissertation was the first large-scale study of structure-activity relationships for adenosine receptors. During a joint postdoc with John W Daly at NIH and Solomon Snyder at Johns Hopkins, he developed the first adenosine receptor binding assay. He then joined WL/PD, where his lab demonstrated the existence of two subtypes of the adenosine A2 receptor, A2a and A2b. In 1988, he joined Lilly as a receptor biologist in charge of a high-throughput screening lab. He taught himself chemoinformatics as a way to optimize compound selection for screening, and in 1997 switched to computational chemistry full-time. He supported the D1 PAM project in various roles from its inception in 2002 until selection of a clinical candidate in 2013. Dr. Bruns has over 80 publications and 11,000 citations, with an h-index of 47. Dr. Robert F. Bruns on the web ResearchGate LinkedIn Dr. GPCR Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Coffee Break 4 Date & Time Friday, November 3rd / 3:00 PM Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

<< Back to podcast list Strategic Partner(s) Mark Schmeizl About Mark Schmeizl Mark leverages 30 years in various life science laboratories & commercial roles with his network of VC & PE contacts to help senior-level life science executives identify new opportunities. He has successfully built numerous global life science, leadership teams, & works closely with both clients & candidates to understand their unique needs & culture. Mark believes professional placement should be about matching talented people with companies where they will thrive, “when the match is right, the results are astonishing.” Dr. Mark Schmeizl on the web Website LinkedIn Dr. GPCR Ecosystem Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Kaavya Krishna Kumar About Dr. Kaavya Krishna Kumar "I am a postdoc in Prof. Brian Kobilka's lab at Stanford University, USA. I work on understanding the activation mechanism of different Families of GPCRs." Dr. Kaavya Krishna Kumar on the web Journal of Biology Chemistry Stanford University Google Scholar LinkedIn Dr. GPCR Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. J. Silvio Gutkind About this episode Have you had moments that defined your scientific tastes? For Dr. J Silvio Gutkind, a class on oncogenes and his interests for GPCRs helped shape his scientific interests. These took him from the University of Buenos Aires in Argentina to UC San Diego and through the National Institutes of Health in Bethesda, Maryland. In this episode, Silvio discusses G protein signaling in the context of cancer, immunotherapies, and combination therapies that could help improve patients’ lives. Dr. J. Silvio Gutkind on the web Dr. J Silvio Gutkind on LinkedIn Gutkind Lab – UC San Diego Moores Cancer Center Gutkind Lab publications Gutkind Lab on Pubmed Gutkind Lab on Twitter UCSD Moores Cancer Center Dr. GPCR Ecosystem Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Pharmacological and Genetic Preclinical Models of Ghrelin Receptor Functional Selectivity to Investigate Metabolic Disease Pathophysiology Date & Time Friday, November 3rd / 9:45 AM Abstract Coming Soon Authors and Affiliations Gross JD -1 (lead author, presenter) Kohlenbach LM -2 Zhou Y -1 Marugan JJ -3 Barak LS -1 (senior author) 1-Department of Cell Biology, Duke University Medical Center, Durham, NC 27710. 2-Department of Biology, Duke Trinity College of Arts and Sciences, Durham, NC 27710. 3-National Center for Advancing Translational Sciences (NCATS), NIH Division of Preclinical Innovation, Rockville, MD 20892. About Joshua Gross "I am a neuropharmacologist interested in exploiting GPCR biased signaling to design/develop new pharmacotherapeutics to treat reward- and metabolism-based diseases, including obesity, eating disorders, and diabetes. I received my PhD in Cellular & Integrative Physiology from West Virginia University under the mentorship of Drs. David Siderovski and Vincent Setola (2014-2019). I am currently completing my postdoctoral research in the laboratory of the late Dr. Marc Caron (2019-2023) and subsequently, will begin my independent research career as a tenure-track Assistant Professor at Penn State University (University Park) in August 2023. My broad research interest is to better understand the underlying mechanisms of food reward and its downstream dysregulation of metabolic function, particularly in response to obesogenic 'Western' diets (aka, ultra-processed food). With my expertise in reward behavior, neurophysiology, GPCR signaling, and preclinical drug development, my lab will strive to develop novel GPCR pharmacotherapies that improve efficacy and minimize side effects for diet-induced metabolic diseases. " Josh Gross on the web Pubmed Google Scholar LinkedIn Twitter Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Dr. Eric Trinquet discusses the science and story behind pH Sense, Revvity’s innovative GPCR internalization assay, and his journey in GPCR product R&D. << Back to podcast list Strategic Partner(s) From Rare Earth Probes to Internalization Assays: The pHSense Story with Dr. Eric Trinquet What does it take to design a breakthrough GPCR assay—from idea to industrial impact? In this special episode, Dr. Eric Trinquet shares the inside story behind the development of pH Sense, Revvity’s latest innovation for tracking GPCR internalization. With a career spanning two decades at the intersection of fluorescence chemistry, functional assays, and product development, Eric takes us through the highs, failures, and scientific “aha” moments that shaped tools like the IP-One kit, Tag-lite, and now, pH Sense. If you’ve ever used HTRF or wondered what goes into making a product worthy of your next experiment, this is your backstage pass. You’ll hear what truly makes a reagent successful—and why academic–industry collaborations are essential for advancing GPCR research. Inside This Episode How Eric and his team reimagined rare earth complexes to develop pH-sensitive probes with tunable brightness and lifetime. Why pH Sense enables high-throughput, no-wash tracking of GPCR internalization—even at endogenous expression levels. What shifted the team’s strategy from traditional calcium assays to IP1 accumulation—and why it mattered for Gq-coupled receptors. How collaborations with David Parker and Jean-Philippe Pin accelerated both probe chemistry and biological validation. What it felt like to see the first dose-response curves in native beta cells—and why that moment changed the trajectory of the project. Why the commercialization of a reagent is not the end, but the beginning of a feedback-driven innovation cycle. Why It Might Hit Home If you’ve ever: Wrestled with unreliable endpoint assays or cumbersome radioactive protocols, Pushed for more physiologically relevant systems and hit the “overexpression ceiling,” Balanced scientific rigor with the unpredictability of product development, Or felt the thrill of seeing a tool you built drive real biological insight… …this episode will resonate. About the Guest Dr. Eric Trinquet is Head of R&D for Life Sciences Reagents at Revvity, where he leads innovation in biochemical and cell-based assay platforms. With a foundational career at Cisbio Bioassays—later acquired by Revvity—Eric played a pivotal role in bringing technologies like HTRF, the IP-One kit, and the Tag-lite platform into widespread use. Originally trained as a physicist with a strong interest in photophysics and fluorescence chemistry, Eric transitioned into the GPCR field through hands-on assay development. His passion lies in turning cutting-edge probe chemistry into robust, scalable tools for drug discovery and basic research. What drives him? A mix of scientific curiosity, a tolerance for failure, and a commitment to delivering real-world impact—one product at a time. More about Revvity pHSense Reagents GPCR Reagents Revvity on Dr. GPCR Dr. GPCR X Revvity Collaboration Want more like this? Join the Dr. GPCR Premium Ecosystem for behind-the-scenes access to GPCR innovators, exclusive deep-dives, and practical tools to accelerate your research or career. 👥 Build connections. 🧪 Get insights. 🎧 Stay ahead. 👉 Join now Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Join us in strengthening the global GPCR community. Your tax-deductible donation supports education, collaboration, and innovation. Dr GPCR is a 501(c)(3) non-profit. Support the GPCR Community — Empower the Next Generation of Discovery Your donation helps us serve the global GPCR community better — by upgrading the Dr GPCR University, creating more learning opportunities, and connecting scientists, students, and biotech innovators. - Secure donation through Wix - Dr. GPCR is a registered 501(c)(3) non-profit organization. 👉 Donate Now Why Donate? Every contribution helps us bridge the gap between academia and biotech — transforming knowledge into real-world impact more quickly. Your donation directly supports: Dr GPCR University : expanding and modernizing our educational programs to make cutting-edge GPCR knowledge accessible to everyone Dr GPCR Retreat: offering free or affordable gatherings that foster collaboration and mentorship across disciplines Happy Hours: informal, community-driven networking events that connect scientists, founders, and innovators in a relaxed setting Job Board: helping researchers and biotech companies find the right opportunities to grow together Community Infrastructure: maintaining the tools and platforms that keep the Dr GPCR Ecosystem open and thriving *Together , we’re creating a global home for everyone passionate about GPCR research, collaboration, and discovery. How Your Gift Helps? Every donation fuels the mission to make GPCR education and collaboration more accessible to everyone in the community. - $25+ 👉 Keeps Dr GPCR Happy Hours and community events free or affordable for participants around the world - $250+ 👉 Expands Dr GPCR University with new lessons, updated materials, and interactive learning modules - $5,000+ 👉 Powers new GPCR educational initiatives — including scholarships, retreats, and mentorship opportunities - $20,000+ 👉 Become a Strategic Partner — recognized across Dr GPCR channels for enabling global collaboration and impact Every contribution, big or small, helps the GPCR community learn, connect, and innovate together. 🎓 Elevate the University — Donate Today ❤️ Donor Recognition We believe generosity deserves visibility. Every donor receives a personal thank-you email and receipt Selected donors are thanked publicly in podcast intros, videos, or events Donations above $20 K are acknowledged as Strategic Partners , featured on our website and community pages Donate Frequency One time One time Monthly Monthly Yearly Yearly Amount $25 $25 $250 $250 $1,000 $1,000 $5,000 $5,000 Other Other 0/300 Comment (optional) Donate $25 FAQ Is my donation tax-deductible? Yes. Dr GPCR is a registered 501(c)(3) non-profit organization. Contributions are tax-deductible to the extent permitted by law. Can I make a donation on behalf of a company? Yes — Use the “Comment” section to add the company name in the donation form, and we’ll provide an invoice/receipt. Can I become a monthly supporter? Absolutely. Monthly donations sustain long-term programs and can be changed at any time. Can I be recognized publicly? Yes — we love thanking our donors through the Podcast, YouTube, and Summit platforms. Help us close the gap between academia and biotech. Together, we can accelerate GPCR discoveries and develop more effective drugs for everyone. 👉 Donate Now to Support the Dr GPCR Ecosystem

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Cannabinoid compounds to augment L-DOPA treatment in Parkinson's Disease Date & Time Friday, November 3rd / 9:20 AM Abstract Coming Soon About Ali Salahpour "Dr. Salahpour did his undergrad (1993-1996) and PhD (1996-2002) at University of Montreal in the Department of Biochemistry. His PhD work was under the supervision of Dr. Michel Bouvier working on the topic of GPCR dimerization/oligomerization. In November of 2002, he joined the lab of Dr. Marc Caron at Duke University for his post-doctoral training. In the Caron lab, Dr. Salahpour worked on Dopamine Transporter and its role on regulating dopamine transmission and homeostasis. In April 2009, he joined the Department of Pharmacology and Toxicology at University of Toronto and has continued working on dopamine transmission and homeostasis and the role of several of key modulators of the dopamine system, including the dopamine transporter (DAT), the Vesicular Monoamine Transporter 2 (VMAT2), Tyrosine Hydroxylase (TH) and Trace Amine Associate Receptor 1 (TAAR1)." Ali Salahpour on the web University of Toronto Pubmed Google Scholar Twitter Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

<< Back to podcast list Strategic Partner(s) Scott Struthers R. Scott Struthers, Ph.D., is our co-founder and has served as our President and Chief Executive Officer since December 2008. Prior to Crinetics, he was senior director and head of endocrinology and metabolism at Neurocrine Biosciences, Inc., from 1998 to 2008. At Neurocrine, he initiated and led the effort to discover and develop orally active, nonpeptide GnRH antagonists, including elagolix. Prior to Neurocrine, from 1995 to 1998, he co-founded ScienceMedia Inc. to develop eLearning solutions for the life sciences and higher education markets. Between 1992 to 1995 he led contract research efforts at Biosym Technologies to develop and apply computational tools for drug discovery. In 2021, Dr. Struthers co-founded and serves as board chair at Radionetics Oncology, a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for oncology indications. In addition, he is a member of the board of directors of the San Diego Entrepreneurs Exchange, a nonprofit organization that provides resources for early-stage start-ups, which he co-founded in [2009.] R. Scott Struthers on the web LinkedIn Google Scholar Crinetics Radionetics Dr. GPCR Ecosystem Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Session VIII Physiological and pathological roles of AGPCRs in the periphery ADGRG1/GPR56 regulates survival of terminally differentiated CD8+ T cells Cheng-Chih Hsiao Adhesion GPCR GPR116/Adgrf5 controls a lineage of anti-thermogenic adipocytes with implications for adaptive thermogenesis during prolonged cold exposure Anastasia Georgiadi ADGRF5-mediated regulation of cardiac health and disease Douglas Tilley ADGRG1/GPR56 regulates survival of terminally differentiated CD8+ T cells Cheng-Chih Hsiao Abstract Only available for AGPCR 24 Attendees Authors & Affiliations "Cheng-Chih Hsiao1,2, Hendrik J. Engelenburg1, Joost Smolders1,3, and Jörg Hamann1,2 1Department of Neuroimmunology, Netherlands Institute for Neuroscience, Amsterdam, The Netherlands; 2Department of Experimental Immunology, Amsterdam institute for Immunology and Infectious diseases, Amsterdam University Medical Center, Amsterdam, The Netherlands; 3MS center ErasMS, Departments of Neurology and Immunology, Erasmus Medical Center, Rotterdam, The Netherlands" About Cheng-Chih Hsiao "2012-2015: PhD in Immunology, University of Amsterdam; 2015-2019: Postdoctoral researcher, Amsterdam UMC; 2019-2022: Senior postdoctoral researcher, Netherlands Institute for Neuroscience; 2022 - present: Researcher associate, Netherlands Brain Bank" Cheng-Chih Hsiao on the web LinkedIn ReseachGate Adhesion GPCR GPR116/Adgrf5 controls a lineage of anti-thermogenic adipocytes with implications for adaptive thermogenesis during prolonged cold exposure Anastasia Georgiadi Abstract Only available for AGPCR 24 Attendees Authors & Affiliations "El Merabhi Rabih1*, Karagiannakou Vasiliki1*, Kardinal Ronja2, Jäckstein Michelle3 Yvonne, Kumar Jha Ankush1, Krokidi Sissy Thodou1, Wachten Dagmar2, Heeren Jörg3, Herzig Stephan1, Georgiadi Anastasia1 *equal contributions , Institutions : 1. Institute for Diabetes and Cancer, Helmholtz Centre Munich, Germany, 2. Institute of Innate Immunity, University Hospital Bonn, University of Bonn, 3. Centre for Experimental Medicine, Institute for Biocehmistry and Molecular Cell Biology, University Medical Center Hamburg-Eppendorf" About Anastasia Georgiadi "Head of Junior Group Endocrine Pharmacology, Institute of Diabetes and Cancer (IDC). Professional Background Since 2021 Group Leader, Institute for Diabetes and Cancer, Helmholtz Diabetes Centre, Munich 2018 - 2021 Project Team Leader, Institute for Diabetes and Cancer, Helmholtz Diabetes Centre, Munich 2015 - 2018 Postdoctoral fellow, Department of Adipose Tissue Biology, Institute for Diabetes and Cancer, Helmholtz Diabetes Centre, Munich 2012 - 2015 Postdoctoral fellow, Department of Cell and Molecular Biology, Karolinska Institute, Sweden" Anastasia Georgiadi on the web Endocrine Pharmacology Google Scholar ADGRF5-mediated regulation of cardiac health and disease Douglas Tilley Abstract Only available for AGPCR 24 Attendees About Douglas Tilley "Research in the Tilley laboratory focuses primarily upon aspects of GPCR regulation of cardiac function, inflammation and remodeling during HF or following acute cardiac injury. Much of this work centered on elucidating novel mechanisms by which β-adrenergic receptors impact cardiac structure and function, and has evolved to encompass their roles in regulating immune cell response to acute cardiac injury or chronic stress. Additionally, the lab has begun to investigate potential roles for previously unrecognized cardiac-expressed GPCRs in the regulation of physiologic/pathologic function in the heart in an effort to uncover novel therapeutic directions for HF, including adhesion GPCRs (AGPCRs). In all, research in the Tilley lab spans molecular pharmacology to pathophysiology studies focused primarily in the cardiovascular realm." Douglas Tilley on the web Lewis Katz School of Medicine at Temple University < Previous Session Next Session >

<< Back to podcast list Strategic Partner(s) Dr. Michael Feigin About Dr. Michael Feigin "Dr. Michael Feigin is an Associate Professor in the Department of Pharmacology and Therapeutics, and Director of Graduate Studies of Experimental Therapeutics at Roswell Park Comprehensive Cancer Center in Buffalo, NY. He earned his Ph.D. under Dr. Craig Malbon at SUNY Stony Brook studying the role of G-protein coupled receptors (GPCRs) and their regulators in the Wnt signaling pathway. Mike then joined the lab of Dr. Senthil Muthuswamy at Cold Spring Harbor Laboratory and probed the roles of polarity proteins (Feigin, et al., Cancer Research, 2014) and GPCRs (Feigin, et al., PNAS, 2014) in breast cancer pathogenesis, using mouse models, three-dimensional cell culture and computational approaches to drug target discovery. When Dr. Muthuswamy moved to the University of Toronto, Mike joined the laboratory of Dr. David Tuveson at CSHL where he participated in the development of an organoid system for the culture of normal and malignant pancreatic tissue, allowing advances in sequencing, target discovery and biomarker development. He also continued his interest in computational analysis of cancer drivers by co-developing GECCO, an algorithm for the identification of noncoding mutations driving gene expression in pancreatic cancer (Feigin and Garvin, et al., Nature Genetics, 2017). Mike's lab has two main areas of interest: 1) alternative polyadenylation as a targetable driver of pancreatic cancer, and 2) dysregulation of the pancreatic tumor microenvironment by commonly prescribed anti-anxiety drugs." Dr. Michael Feigin on the web Roswell Park Feigin Lab Google Scholar LinkedIn Twitter Dr. GPCR AI Summary AI-generated content may be inaccurate or misleading. Always check for accuracy. Quick recap Yamina and Mike engaged in a conversation about their scientific research experiences. Mike shared his journey from his Ph.D. struggles to his current role as a professor, emphasizing the importance of resilience and creativity. They also discussed his research on cell polarity and its role in cancer progression, his work on G-protein coupled receptors (GPCRs) in breast cancer, and his interest in pancreatic cancer. The discussion also covered the challenges they face in studying GPCRs due to their low expression levels and the difficulty of localizing these receptors in tissues. Next steps • Mike will consider using Twitter to post job positions in his lab. Summary Science Roles and Resilience Yamina and Mike had a conversation about their roles and experiences in the field of science. Yamina introduced herself and Mike shared his educational background and his journey to becoming a professor. Mike also spoke about his initial struggles during his Ph.D., such as a difficult model system and a lack of experimental results. He explained that he overcame these challenges by reading extensively and contemplating alternative plans. The conversation also highlighted the importance of resilience and creativity in scientific research. Science Journey and Postdoc Decision Mike discussed his journey into science and his decision to pursue a postdoc at Cold Spring Harbor. He shared that his interest in science originated from a young age and his desire to gain more knowledge about cancer biology led him to transition into using mouse models. Yamina asked about his move from in vitro to in vivo work, and Mike explained that he wanted to use better models to understand cancer signaling pathways. They also shared their personal experiences and interest in the field of biology. Towards the end, Mike mentioned that he stayed at Cold Spring Harbor even after his mentor left for Toronto. Mike's Research on Cell Polarity and GPCRs in Cancer Mike shared his research on cell polarity and its role in cancer progression, particularly focusing on the potential of disrupted cell polarity as a driver of tumorigenesis. He also discussed his work on G-protein coupled receptors (GPCRs) in breast cancer, identifying GPR161 as a potential drug target due to its high expression in triple negative breast cancer. Mike then transitioned to pancreatic cancer, questioning why genes are dysregulated in cancer, which led him to explore different aspects of gene regulation and its relation to cancer progression. Yamina acknowledged the difficulty in identifying GPCRs expressed in cancer cells but not in normal ones, and commended Mike's innovative approach to the question. Career Trajectory and Faculty Position Yamina and Mike discussed Mike's career trajectory and his decision to pursue a faculty position. Mike expressed his initial reluctance due to a lack of confidence and fear of not being ready. However, he decided to undertake another postdoc to gain more experience and confidence. He also highlighted the importance of publishing strong papers and having a clear vision for his lab. Yamina emphasized the importance of thorough preparation and planning before applying for faculty positions. They also discussed the challenges of the two-body problem, where both partners need to find suitable positions. Mike shared his strategy of developing preliminary projects and gathering data to strengthen his application. Teamwork and Flexibility in Scientific Research Mike shared about his recent promotion and the way he has managed his team, encouraging them to come up with their own ideas and then guiding them. Yamina congratulated Mike on his promotion and discussed the importance of flexibility in scientific research, even when starting with a clear plan. Mike also mentioned how his team collaborates closely, with weekly roundtable discussions where everyone shares their progress and issues. The conversation ended with Yamina expressing interest in learning more about Mike's two main research areas in his lab. GPCR Targeted Drugs and Gene Regulation in Cancer Cells Mike presented research on the effect of GPCR-targeted drugs on cancer-associated fibroblasts and discussed their work on gene regulation in fibroblasts. He highlighted their interest in non-coding mutations in promoters and the 3'UTR region important for gene regulation. Mike also shared about a drug that targets an enzyme involved in mRNA cleaving, which has been found to stop cancer cells from growing and invading. He also discussed the impact of disrupting histone processing on rapidly proliferating cells, such as cancer cells, and suggested a therapeutic index for a drug called JTE-6.7. Yamina asked about the typical role of the enzyme and the challenges in delivering a molecule to target this enzyme and only cancer cells. Cytokine Inhibition, Collaboration, and Anti-Anxiety Drug Research Mike discussed the ongoing research on a drug that inhibits cytokine synthesis, its potential in killing cancer cells, and the team's efforts to understand its resistance mechanisms. He also touched upon a collaboration with Todd Ricky's group at UPenn to explore the GPCR side of the lab, which led to the discovery of potential tumor suppressors and oncogenes in melanoma. Furthermore, Mike mentioned a qualifying exam where students proposed new projects, highlighting Abby Cornwell's project on the effects of anti-anxiety drugs on pancreatic cancer patients, and the team's research on the potential issues with certain anti-anxiety drugs. The team found that these drugs could interact with GPR68, which is highly expressed in cancer-associated fibroblasts and is crucial for their function, leading to complications in cancer patients. The team is now examining other anti-anxiety drugs and common patient medications in the context of pancreatic cancer. GPCRs and Cancer Immune Modulation Yamina and Mike had a discussion about their research on GPCRs, specifically focusing on GPR68 and its role in the tumor microenvironment. They also touched upon the potential of GPCR modulation in stimulating the immune system to fight cancer. Mike shared his team's current focus on alprazolam, an anti-anxiety medication that has unexpected effects in the tumor microenvironment. They also discussed the challenges they face in studying GPCRs due to their low expression levels and the difficulty of localizing these receptors in tissues. Mike expressed a need for better tools to study GPCR localization in tissues. Scientific Journey and Drug Discovery Challenges Mike shared significant moments in his scientific journey, including the discovery of RGS proteins and its impact on his research approach. He also discussed his experiments and discoveries about GPR161 in mammary epithelial cells, the effect of alprazolam on tumors, and the potential dangers of drug interactions. Yamina proposed further exploration of dosage and length of treatment in a mouse model and suggested using a biosensor-based assay to examine dose-response curves. The conversation highlighted the complexities and challenges of drug prescription and the potential for alternative treatments. Science Journeys and Career Advice Yamina and Mike discussed their experiences in the field of science. Mike advised junior scientists to focus on projects they are passionate about, emphasizing that ownership and full investment in a project can make dealing with challenges easier. Yamina shared her personal journey, describing how she took her project in a different direction and felt a sense of ownership. Mike reflected on his early years as a postdoc, admitting that he lacked focus and didn't see the direct impact of his work on patients. He highlighted the importance of re-evaluating one's work and its potential implications. Towards the end, Yamina asked about job opportunities in Mike's lab, to which Mike responded that potential candidates can find him on Twitter. Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Oliver Hartley About Dr. Oliver Hartley Oliver Hartley is VP for Drug Discovery at Orion Biotechnology . He is the inventor of OB-002 as well as the key technology underlying Orion’s discovery platform. Trained as a biochemist, he completed a PhD in protein engineering (Cambridge, UK) with Sir Gregory Winter (Nobel Prize for Chemistry, 2018). Since then Oliver has worked at the University of Geneva, where his research on peptide engineering and GPCR pharmacology has led to a series of high-profile publications and new intellectual property, and at the Mintaka Foundation for Medical Research with a role as co-founder and Chief Scientific Officer. Dr. Oliver Hartley on the web LinkedIn Orion Biotechnology Dr. GPCR Ecosystem Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Graciela Pineyro About this episode: Dr. Graciela Pineyro is a professor of pharmacology at the department of pharmacology and physiology of the University of Montreal. She has done extensive work on the molecular pharmacology of opioid receptors and is currently focusing on the pharmacology of cannabinoids in the context of pain. We chatted about how the current pandemic has affected her personally and professionally. Dr. Graciela Pineyro on the web Dr. Graciela Pineyro on LinkedIn Dr. Graciela Pineyro - University of Montreal Dr. Graciela Pineyro - CHU Ste-Justine Research Centre Pineyro Lab Publications on Google Scholar Pineyro Lab on Pubmed Dr. GPCR Ecosystem Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Marta Filizola About Dr. Marta Filizola Dr. Marta Filizola is the Sharon & Frederick A. Klingenstein-Nathan G. Kase, MD Professor in the Departments of Pharmacological Sciences, Neuroscience, and Artificial Intelligence and Human Health, as well as the Dean of The Graduate School of Biomedical Sciences at the Icahn School of Medicine at Mount Sinai, in New York, USA. The overall goal of her research program is to obtain rigorous mechanistic insights into the structure, dynamics, and function of important classes of membrane proteins and prominent drug targets, including G protein-coupled receptors (GPCRs), transporters, channels, and 3 integrins. To this end, her lab uses several computational structural biology tools and rational drug design approaches, ranging from molecular modeling, bioinformatics, cheminformatics, molecular dynamics simulations, free-energy perturbations, machine learning, etc. A native of Italy, she received her Bachelor’s and Master’s degrees in Chemistry from the University Federico II in Naples. She pursued a Ph.D. in Computational Chemistry at the Second University of Naples and a postdoctorate in Computational Biophysics at the Molecular Research Institute in California, USA. Dr. Marta Filizola on the web Icahn School of Medicine at Mount Sinai Filizola Lab Wikipedia Twitter Linkedin ResearchGate Google Scholar Orcid PubMed Dr. GPCR Ecosystem Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Join the forefront of GPCR research at the Dr. GPCR Summit! Embracing innovation and technology, we connect global scientific communities. Experience talks spanning time zones, with options for live or pre-recorded presentations. Uncover groundbreaking insights in GPCR science together. Learn more. Dr. GPCR Summit We live in a new world, and we think it's an opportunity to try new things and use current technologies to help us connect and spread scientific advances in the GPCR field. Our goal is to allow everyone in the GPCR community to get access to the talks through the entire length of the event independently of their time zone. This means that presenters will have the option of providing a pre-recorded talk or giving a live presentation. More information is outlined below. See Schedule See Schedule See Schedule

<< Back to podcast list Strategic Partner(s) Dr. Lauren M. Slosky About Dr. Lauren M. Slosky Lauren Slosky is an Assistant Professor in the Department of Pharmacology and a member of the Medical Discovery Team on Addiction, a multidisciplinary initiative within the University of Minnesota’s Medical School to advance research and treatment in the field of drug addiction. Dr. Slosky’s research is focused on understanding how neuropeptide G protein-coupled receptors (GPCRs) regulate motivated behavior and how these receptors can be targeted for therapeutic benefit. Dr. Slosky was awarded a B.S. with honors in Molecular and Cellular Biology and Psychology from The University of Arizona in 2011. She received a Ph.D. in Medical Pharmacology from The University of Arizona in 2015 and completed a postdoctoral fellowship in the laboratory of Dr. Marc G. Caron at Duke University. Dr. Slosky opened her laboratory at the University of Minnesota Medical School in 2021. While a postdoctoral fellow, Dr. Slosky characterized a new class of β-arrestin biased allosteric modulators (BAMs) for the neurotensin receptor 1. These ligands stimulate receptor β-arrestin recruitment without activating canonical G protein signaling. Critically, these ligands reduce addiction-associated behaviors in animal models without the side effects characteristic of balanced receptor activation. Because BAMs engage less well-conserved allosteric sites and exert pathway-specific effects on receptor signaling, they are exciting tools for linking distinct signaling pathways with their physiological effects and may serve as the basis for more selective therapeutics. This work was made possible by the optimization of longitudinal intravenous self-administration paradigms for genetically modified mice. Integrating GPCR biology, behavioral pharmacology, and systems neuroscience approaches, the Slosky Lab is now working to understand how the principles of receptor allosterism and functional selectivity can be leveraged in the development of safe and effective treatments for stimulant and opioid use disorders. Dr. Slosky’s work has been recognized through several travel and research awards, including the William James Psychology Award, the Hank Yamamura Endowed Fellowship in Pharmacology, an NIH F32 Postdoctoral Fellowship, and an NIH K99/R00 Pathway to Independence Award. In addition to research, Dr. Slosky is passionate about training the next generation of scientists and increasing diversity, equity, and inclusion in science. An advocate for trainees at all levels, she served as Service Chairperson and Interim President of the Duke University Postdoctoral Association. She is currently a faculty trainer for the University of Minnesota's MS and Ph.D. programs in Pharmacology, Graduate Program in Neuroscience, and Life Sciences Summer Undergraduate Research Program and is working to build relationships with key stakeholders through institutional and community service. Dr. Lauren M. Slosky on the web Twitter University of Minnesota Department Page LinkedIn Google Scholar PubMed Research Gate Dr. GPCR Ecosystem Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Complex Allosteric Cannabinoid Receptor Pharmacology Date & Time Friday, November 3rd / 11:30 AM Abstract Coming Soon About Robert Laprairie "Dr. Robert Laprairie is an Associate Professor and the Saskatchewan Research Chair in Drug Discovery and Development at the College of Pharmacy and Nutrition, University of Saskatchewan. Robert was the President and Director of Education for the Canadian Consortium for the Investigation of Cannabinoids (CCIC) and the 2021 Recipient of the William A. Devane Young Investigator Award from the International Cannabinoid Research Society (ICRS). Robert and his lab have been interested in the molecular pharmacology of cannabinoids for nearly 10 years and he has published more than 50 studies in the field." Robert Laprairie on the web University of Saskatchewan Pubmed Twitter Instagram ResearchGate Google Scholar Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Closing remarks < Previous Session Next Session >

<< Back to podcast list Strategic Partner(s) You never know where your GPCR takes you with Dr. Brian Hudson About Brian Hudson Brian is a lecturer in the School of Molecular Biosciences at the University of Glasgow. He has more than 20 years of experience in GPCR, primarily focused on drug discovery and developing new tools to study this receptor family. He leads a research group that is focused on understanding the pharmacology and function of a group a GPCRs that are activated by metabolic intermediates. Brian Hudson on the web University of Glasgow Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

No plans available Once there are plans available for purchase, you’ll see them here.

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Developing a PROTAC to Degrade the Constitutively Active Onco-GPCR in Uveal Melanoma Date & Time Friday, November 3rd / 4:20 PM About Victoria Rasmussen "Victoria Rasmussen is a graduate fellow in Dr. Thomas Sakmar’s laboratory at Rockefeller University, where she studies the signaling and degradation of G protein-coupled receptors. She completed her undergraduate education at Providence College, receiving a B.S. in Biology and a B.A. in Psychology. During her time at Providence College, she received the Walsh Grant Fellowship to develop novel methods of synthesizing 2-imidazoline scaffolds to be used as proteasome modulators in the laboratory of Travis Bethel. Victoria started her Ph.D. at the Tri-Institutional Ph.D. program in Chemical Biology, where she joined the lab of Thomas Sakmar at Rockefeller University. She is currently working to understand the signaling and degradation of GPCRs in disease states to help test the feasibility of using protein-targeted degradation as a therapeutic strategy. " Victoria Rasmussen on the web Tri-Institutional PhD Program Chemical Biology LinkedIn Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Registration & Coffee with light breakfast < Previous Session Next Session >

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Dopamine-Mediated Motor Recovery after Ischemic Stroke Date & Time Friday, November 3rd / 8:30 AM Abstract Coming Soon About Mario Tiberi "I did my graduate research on the regulation of axonal transport by tricyclic antidepressants (M.Sc.) and molecular pharmacology of opioid receptors (Ph.D.) in the Department of Pharmacology at the Université de Montréal under the mentorship of Dr. Pierre-André Lavoie and Dr. Jacques Magnan, respectively. I then pursued my postdoctoral training at Duke University in the laboratory of Dr. Marc Caron, where I cloned the dopamine D5 receptor gene and investigated the regulation of dopaminergic and adrenergic receptors. My addiction for dopamine led me to the Ottawa Hospital Research Institute (then the Moses and Rose Loeb Research Institute) to develop my independent research program. The Tiberi Lab pursues the study of the molecular, structural, pharmacological and signaling features of dopamine (DA) receptors. We are also currently developing the translational component of our research to capitalize on the druggability potential of GPCRs. More specifically, we investigate the druggability potential of new signaling partners we identified that drive the formation of different DA receptor complexes. We hope our research will aid in the development of new therapeutic interventions for the alleviation of L-DOPA-induced dyskinesia in Parkinson’s Disease and improvement of post-stroke recovery." Mario Tiberi on the web University of Ottawa Pubmed Google Scholar ResearchGate LinkedIn Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Discover how Celtarys Research is transforming GPCR assay development with fluorescent ligands in this episode featuring CSO Dr. Maria Majellaro—and learn what their new partnership with Dr. GPCR means for the global research community. << Back to podcast list Strategic Partner(s) Custom Molecules, Fluorescent Probes: When Chemists Think Like Biologists with Dr. Maria Majellaro from Celtarys A Partnership Rooted in Scientific Innovation In this episode, Dr. Maria Majellaro, CSO of Celtarys Research, shares the story behind the company’s journey from academic curiosity to biotech force. But this conversation also marks something new: a strategic partnership between Dr. GPCR and Celtarys, built on a shared commitment to empowering the GPCR research community. At Celtarys, the focus is on enabling fast, customizable development of fluorescent ligands and chemical probes for GPCR assays. What started as a PhD project has grown into a commercial technology that helps scientists interrogate receptor pharmacology with greater speed and flexibility. “We started with GPCRs, but now we’re expanding to many new targets. Every time, it’s a new world—and we’re still learning.” — Maria Majellaro Through this partnership, Celtarys becomes an integral part of the Dr. GPCR ecosystem, contributing both expertise and tools that align directly with the needs of scientists at the bench and in translational drug discovery. Decision-Making: From Researcher to Scientific Leader Maria’s story is one of trusting her instincts while embracing change. She began as a medicinal chemist in Italy, but a postdoc opportunity in Santiago de Compostela—and a mentor’s timely suggestion—changed her trajectory. When the time came to decide whether to leave the lab and lead Celtarys into biotech, she took the leap. “It was my shift from the lab to leadership. I wasn’t sure at first, but I realized I could do this too.” — Maria Majellaro Her decisions, often made intuitively rather than analytically, have led to key inflection points—including Celtarys’ formal launch in 2021, just as the world was emerging from the pandemic. Now, she leads a team of six scientists and continues to build momentum through collaborations like the one with Dr. GPCR. Translating Science into Business Like many scientists-turned-entrepreneurs, Maria faced the challenge of learning the business side of biotech on the fly. Celtarys had the technology—but not the roadmap for commercialization. That changed with support from Galicia’s robust biotech network, and the company quickly defined its value: building better tools for drug discovery assays. “As scientists, we know how to make molecules. But we had to learn everything else—IP, market positioning, customer discovery.” — Maria Majellaro This year, as part of its partnership with Dr. GPCR, Celtarys will bring those lessons to the broader community, providing insight into assay development, probe design, and the realities of scaling innovation from lab bench to product launch. The Complexity Behind Every “Successful” Probe Maria is candid about the technical challenges behind fluorescent ligand development. “It’s not just attaching a fluorophore,” she says. Each probe must retain activity, remain soluble, and be compatible with a given assay format. There were moments of doubt and repeated optimization. The payoff? Enabling companies and academic labs to avoid the costly dead ends often associated with probe development. “You can have a great ligand—but if you can’t solubilize it, it’s useless.” — Maria Majellaro Celtarys’ unique chemical platform shortens development timelines and allows tailored modifications—critical for labs starting new GPCR-related projects. Their work directly supports the tool-building mission that aligns with the Dr. GPCR ecosystem. Pivoting: From Chemistry Company to Discovery Partner Initially focused on tool production, Celtarys has evolved into something more: a scientific collaborator. Their approach is highly consultative—they don’t just sell ligands, they co-develop solutions. The company works with clients from pharma, CROs, and academia, including MD Anderson and several leading GPCR labs. “We always start with the problem, then generate the right compound using our chemistry. It’s about enabling biology.” — Maria Majellaro Through its partnership with Dr. GPCR, Celtarys will expand its visibility and impact—offering its expertise, tools, and real-world insight to researchers tackling today’s most pressing GPCR-related questions. Key Takeaway This episode is more than a conversation—it’s the official kickoff of a one-year partnership between Dr. GPCR and Celtarys. Together, we’re combining chemistry, biology, and business insight to empower the GPCR research community like never before. Whether you're designing assays, developing probes, or seeking better tools for GPCR drug discovery, Celtarys and Dr. GPCR are now working hand-in-hand to help you do it faster, better, and more reproducibly. About Maria Majellaro Dr. Maria Majellaro obtained her PhD with the distinction of Doctor Europeus from the Department of Pharmacy at the University of Bari (Italy) in 2018. During her doctoral studies, she spent one year as a predoctoral visiting student at the CIQUS Research Center—Campus of International Excellence—in Santiago de Compostela (Spain). In 2018, she returned to CIQUS to work as a Postdoctoral Research Associate in the group of Prof. Eddy Sotelo, where together with Dr. Jhonny Azuaje they laid the groundwork for the future creation of Celtarys Research. Since the founding of Celtarys in 2021, she has served as the company’s Chief Scientific Officer, leading all scientific activities—from the development of Celtarys’ proprietary products to the ideation and execution of custom research projects. She also oversees the company’s scientific collaborations across Europe and beyond, being responsible for securing and managing national and international research grants. To date, she has successfully led seven funded projects. Her scientific expertise is rooted in organic synthesis and medicinal chemistry, with a particular focus on GPCR modulators. She has played a central role in the development and validation of Celtarys’ proprietary synthetic technology and is both a co-author of the related patent and a co-founder of the company. Maria Majellaro on the web LinkedIn ResearchGate Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Coffee Break 1 Date & Time Thursday, November 2nd / 2:45 PM Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

<< Back to podcast list Strategic Partner(s) Dr. G. Aditya Kumar About Dr. G. Aditya Kumar Dr. Aditya Kumar is a postdoctoral fellow at the University of Michigan Medical School. Aditya is interested in understanding the role of the membrane microenvironment in the subcellular organization, trafficking, and signaling of GPCRs. He received his Ph.D. from the Centre for Cellular and Molecular Biology at Hyderabad, India, where he studied the interaction of membrane cholesterol with the serotonin-1A receptor and its effects on receptor signaling and endocytosis. In addition, he explored the role of the host membrane in the entry of intracellular pathogens into macrophages. He currently uses high-resolution fluorescence microscopy and biochemistry to study GPCR trafficking mechanisms. In his (future) independent research career, Aditya aims to work at the interface of GPCR molecular pharmacology, subcellular trafficking, and membrane biology to better understand how the dynamic receptor microenvironment contributes to GPCR organization and function. Dr. G. Aditya Kumar on the web University of Michigan Puthenveedu Lab Google Scholar NIH ORCID LinkedIn Twitter Dr. GPCR Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Khaled Abdelrahman, Victoria Rasmussen and Madelyn Moore About Dr. Khaled Abdelrahman " Dr. Khaled Abdelrahman graduated in 2006 with a BSc in Pharmaceutical Sciences from Alexandria University (Egypt) followed by MSc in Pharmacology in the same university that was conferred in 2009. He joined the laboratory of Dr. William Cole at the University of Calgary in 2010 for his Ph.D. where he studied the molecular basis underlying altered cerebrovascular function and blood flow in type 2 diabetes. In 2015, He joined Dr. Stephen Ferguson’s laboratory in the Departments of Cellular & Molecular Medicine and Neuroscience at the University of Ottawa as a Postdoctoral Fellow to explore novel G protein-coupled receptor (GPCR) candidates that can be targeted pharmacologically to slow neurodegeneration. He has been also studying what aspects of GPCR signaling are regulated in a sex-selective manner and how this can influence drug discovery in the area of neurodegenerative diseases. He is also a Registered Pharmacist in Canada and held two of the most prestigious Clinician Postdoctoral Fellowships offered by Alberta Innovates and Canadian Institutes of Health Research. He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics. " Dr. Khaled Abdelrahman on the web Twitter PubMed Google Scholar Dr. GPCR About Victoria Rasmussen "Victoria Rasmussen is a graduate fellow in Dr. Thomas Sakmar’s laboratory at The Rockefeller University, where she study’s the signaling and degradation of G protein-coupled receptors. She completed her undergraduate education at Providence College, receiving a B.S. in Biology and a B.A. in psychology. During her time at Providence College, she received the Walsh Grant Fellowship to develop novel methods of synthesizing 2 -imidazoline scaffolds to be used as proteasome modulators in the laboratory of Travis Bethel. Victoria started her Ph.D. at the Tri-Institutional Ph.D. program in Chemical Biology, where she joined the lab of Thomas Sakmar at The Rockefeller University. She is currently working to understand the signaling and degradation of GPCRs in disease states to help test the feasibility of using protein-targeted degradation as a therapeutic strategy. " Victoria Rasmussen on the web Tri-Institutional PhD Program in Chemical Biology Rockefeller University LinkedIn Dr. GPCR About Madelyn Moore "Madelyn (Maddi) earned her B.S. in Biochemistry from the University of Minnesota-Duluth in 2020. In her time as an undergraduate, Maddi was a researcher in Dr. Amanda Klein's lab where she helped to investigate the role of various ATP-sensitive potassium channels in pain and opioid tolerance. From there, she went on to be a research technologist in Dr. Richard Vile's lab at Mayo Clinic where she aided the evaluation of tumor-specific oncolytic viruses. Maddi is currently a second year Ph.D. student in the Molecular Pharmacology and Therapeutics (MPaT) Graduate Program at the University of Minnesota. Advised by Dr. Lauren Slosky, she is working to understand the mechanism by which a new class of biased allosteric modulators for the neurotensin receptor 1 (NTSR1) act to attenuate the behavioral effects of methamphetamine." Madelyn Moore on the web MPaT PubMed LinkedIn Dr. GPCR Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

< Back to Vault Title I'm a paragraph. I'm connected to your collection through a dataset. Click Preview to see my content. To update me, go to the Data Manager. This Vault is available to Dr. GPCR Premium members. Built for founders who prefer clarity over chaos and confusion. Biotech Decision Vault by Attila Foris Strategic Business & Operating Systems Advisor Dr. GPCR Ecosystem